Clinical Trials
5 trialsNCT05386108 2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT07198724 2026-04-09
ERADICATE
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT05963997 2026-03-23
SUMIT-ELA
Carrick Therapeutics Limited
Phase 1/2 Completed
NCT05618613 2025-05-09
ELONA
Context Therapeutics Inc.
Phase 1/2 Terminated
NCT06938711 2025-04-22
A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer
Context Therapeutics Inc.
Phase 1/2 Withdrawn